Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is a clinical-stage biopharmaceutical company with a promising portfolio focused on developing innovative and proprietary treatments for Treatment-Resistant Depression (TRD). Despite some potential regulatory and competitive risks, their lead product candidate GH001 has shown impressive efficacy and potential for significant revenue in the US market. With a strong management team and a promising Phase III trial underway, GH Research has a positive outlook for long-term success and potential for significant growth.

Bears say

GH Research is a clinical-stage biopharmaceutical company that was founded in 2018, and while it currently has a strong financial position, with over $362 million in cash, it has significant development, regulatory, and commercial risks ahead. These risks include potential issues with the FDA in lifting the clinical hold on GH001 and potential competition from more efficacious products if GH001 is approved. Further risks include the potential failure to secure financing for the pivotal Phase 3 trial and commercialization. GH Research is focusing on developing therapeutics for psychiatric and neurologic disorders, but the success of its lead product candidates, GH001 and GH002, is uncertain given the significant risks involved in their development and potential competition in the market.

GHRS has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.